相关产品推荐更多 >

SARS-CoV-2 Spike RBD (E484A) Protein (His Tag)
¥4500
新冠病毒阿尔法B.1.1.7 Spike S1+S2三聚体蛋白
¥5820
乙型流感 (B/Brisbane/60/2008) Nucleoprotein / NP 重组蛋白 (His Tag)
¥5170
Hemagglutinin/HA重组蛋白|Recombinant H1N1 HA-specific B cell probe(Y108F, AVI & His Tag),Biotinylated
¥4520
Influenza A H1N1 (A/swine/Mexico/AVX47/2013) Hemagglutinin / HA Protein (His Tag)
¥4520
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
-20℃ to -80℃
- 保质期:
12个月
- 英文名:
Recombinant Human coronavirus(HCoV-OC43)Spike Protein(S1+S2 ECD, His Tag)
- 库存:
99
- 供应商:
北京义翘神州科技股份有限公司
- 规格:
100.00 µg
Human coronavirus (HCoV-OC43) Spike Protein (S1+S2 ECD, His Tag): 产品信息
纯度> 85 % as determined by SDS-PAGE.
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
生物活性
Testing in progress
蛋白构建
A DNA sequence encoding the human coronavirus (HCoV-OC43) spike protein (S1+S2 ECD) (AVR40344.1) (Met1-Pro1304) was expressed with a polyhistidine tag at the C-terminus.
表达宿主
Baculovirus-Insect Cells
种属
HCoV-OC43
预测 N 端
Phe 13
分子量
The recombinant human coronavirus (HCoV-OC43) spike protein (S1+S2 ECD, His Tag) consists of 1303 amino acids and predicts a molecular mass of 145.1 kDa.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
1, Yu J, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition.Blood, PubMed ID: 32877502
2, Liu T, et al. Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates.Nature biomedical engineering, PubMed ID: 33122853
3, Anderson EM, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.medRxiv : the preprint server for health sciences, PubMed ID: 33200143
4, Sakharkar M, et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection.Science immunology, PubMed ID: 33622975
5, Klausberger M, et al. A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests.EBioMedicine, PubMed ID: 33906067
6, Ravindran R, et al. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses.PloS one, PubMed ID: 34242356
7, Jennewein MF, et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.Cell reports, PubMed ID: 34237283
8, Natarajan H, et al. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.mBio, PubMed ID: 33879585
9, Wratil PR, et al. Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.Cell reports, PubMed ID: 34932974
10, Lin CY, et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response.Cell host & microbe, PubMed ID: 34965382
11, Narowski TM, et al. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.Cell reports, PubMed ID: 35090596
12, Lederer K, et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals.Cell, PubMed ID: 35202565
13, Pattinson D, et al. A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs.Viruses, PubMed ID: 35336970
14, Minervina AA, et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells.medRxiv : the preprint server for health sciences, PubMed ID: 34341799
15, Lanz TV, et al. Limited Neutralization of Omicron by Antibodies from the BNT162b2 Vaccination against SARS-CoV-2.Research square, PubMed ID: 35441169
16, Minervina AA, et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells.Nature immunology, PubMed ID: 35383307
17, Sun X, et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2.Nature microbiology, PubMed ID: 35773398
18, Anderson EM, et al. SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations.Cell reports, PubMed ID: 36261003
19, López-Muñoz AD, et al. Cell Surface Nucleocapsid Protein Expression: A Betacoronavirus Immunomodulatory Strategy.bioRxiv : the preprint server for biology, PubMed ID: 36993159
20, Ravindran R, et al. Dynamics of temporal immune responses in nonhuman primates and humans immunized with COVID-19 vaccines.PloS one, PubMed ID: 37856429
21, Dos Santos Alves RP, et al. Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice.Nature communications, PubMed ID: 38278784
22, Sibille G, et al. The Novel A-Type Proanthocyanidin-Rich Phytocomplex SP4™ Acts as a Broad-Spectrum Antiviral Agent against Human Respiratory Viruses.International journal of molecular sciences, PubMed ID: 39000477
23, Li Z, et al. Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination.Immunity, PubMed ID: 39168129
2, Liu T, et al. Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates.Nature biomedical engineering, PubMed ID: 33122853
3, Anderson EM, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.medRxiv : the preprint server for health sciences, PubMed ID: 33200143
4, Sakharkar M, et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection.Science immunology, PubMed ID: 33622975
5, Klausberger M, et al. A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests.EBioMedicine, PubMed ID: 33906067
6, Ravindran R, et al. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses.PloS one, PubMed ID: 34242356
7, Jennewein MF, et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.Cell reports, PubMed ID: 34237283
8, Natarajan H, et al. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.mBio, PubMed ID: 33879585
9, Wratil PR, et al. Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.Cell reports, PubMed ID: 34932974
10, Lin CY, et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response.Cell host & microbe, PubMed ID: 34965382
11, Narowski TM, et al. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.Cell reports, PubMed ID: 35090596
12, Lederer K, et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals.Cell, PubMed ID: 35202565
13, Pattinson D, et al. A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs.Viruses, PubMed ID: 35336970
14, Minervina AA, et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells.medRxiv : the preprint server for health sciences, PubMed ID: 34341799
15, Lanz TV, et al. Limited Neutralization of Omicron by Antibodies from the BNT162b2 Vaccination against SARS-CoV-2.Research square, PubMed ID: 35441169
16, Minervina AA, et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells.Nature immunology, PubMed ID: 35383307
17, Sun X, et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2.Nature microbiology, PubMed ID: 35773398
18, Anderson EM, et al. SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations.Cell reports, PubMed ID: 36261003
19, López-Muñoz AD, et al. Cell Surface Nucleocapsid Protein Expression: A Betacoronavirus Immunomodulatory Strategy.bioRxiv : the preprint server for biology, PubMed ID: 36993159
20, Ravindran R, et al. Dynamics of temporal immune responses in nonhuman primates and humans immunized with COVID-19 vaccines.PloS one, PubMed ID: 37856429
21, Dos Santos Alves RP, et al. Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice.Nature communications, PubMed ID: 38278784
22, Sibille G, et al. The Novel A-Type Proanthocyanidin-Rich Phytocomplex SP4™ Acts as a Broad-Spectrum Antiviral Agent against Human Respiratory Viruses.International journal of molecular sciences, PubMed ID: 39000477
23, Li Z, et al. Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination.Immunity, PubMed ID: 39168129
技术资料暂无技术资料 索取技术资料
文献支持
Coronavirus spike重组蛋白|Recombinant Human coronavirus(HCoV-OC43)Spike Protein(S1+S2 ECD, His Tag)
¥5820





